Standigm

The workflow AI drug discovery company

Founded 2015

Korea South 23 employees Growth Total: $78.57M AI, Biotechnology +3

General Information

Company Name Standigm

Founded Year 2015

Location

Korea South

Founders / Decision Makers

Employees 23

Industries AI, Biotechnology, Health Care +2

Funding Stage Growth

Business Model B2B, SaaS, Platform

Revenue Model Subscription, Licensing, Performance Based

Offices as of Nov 2026

‏Seoul‏، ‏06234‏، ‏KR‏, ‏Seoul‏، ‏06234‏، ‏KR‏ ‏Cambridge‏، ‏England‏ ‏CB1 2JH‏، ‏GB‏, ‏Cambridge‏، ‏England‏ ‏CB1 2JH‏، ‏GB‏ ‏Cambridge‏، ‏MA‏ ‏02142‏، ‏US‏, ‏Cambridge‏، ‏MA‏ ‏02142‏، ‏US‏

Social

BounceWatch is an independent company data service, not affiliated with Standigm. To contact Standigm, visit standigm.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Standigm compare?

A PDF of Standigm and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Standigm soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

From the desk

Is Standigm on your competitive set?

Our desk can watch it and brief you on every move: hiring, funding, leadership, product and pricing.

Book a 7-day Readout

Discover More

Korea South Market

Market Signals All Companies

Industry Signals All Companies in Korea South

Standigm Alternatives

All Signals Trend Reports

AI Insight

Bounce Watch AI

1 month ago

Standigm is strategically accelerating its drug discovery and commercialization efforts, evidenced by a new R&D partnership with Protai to develop molecular glue degraders. The company has also gained significant national recognition, being accepted into Korea's Advanced Drug Target Discovery program. Concurrently, Standigm is actively pursuing global pharmaceutical collaborations to commercialize its AI drug discovery platform, STELLA, and its lead compound, MP103, signaling a strong drive for market penetration and pipeline development.

Signal Types

Partnership Recognition Business Development

Strategic Labels

R&D Collaboration Global Expansion Strategic Validation

Next Move: Commercialization

Impact: 8/10

Ideal For: Growth Equity VCs - AI Drug Discovery

About Standigm

Standigm, founded in 2015, is a Korean-based company specializing in AI-driven drug discovery. With its slogan, "The workflow AI drug discovery company," Standigm leverages cutting-edge proprietary AI platforms to revolutionize the drug development process. It offers a comprehensive solution encompassing novel target identification, lead generation, and drug repurposing, thus streamlining the path to developing commercially viable drug pipelines.

The company takes pride in its innovative early-stage AI-driven workflow, which notably reduces the timeline to generate First-in-Class lead compounds to just seven months. Key platforms like DarkMolFactory™, Standigm ASK™, Standigm BEST™, and Standigm Insight™ automate and optimize various phases of the drug discovery process, potentially saving time and resources.

Standigm last secured a $10.00M growth equity investment from Pavilion Capital on 01 July 2021, highlighting investor confidence in their vision and technological advancements in the fields of AI, Biotechnology, Health Care, Pharmaceutical, and Machine Learning.

Business keywords: AI-driven Drug Discovery, Workflow Automation, Molecular Design, Novel Target Identification, Lead Compound Generation, First-in-Class Drug Development, Target Discovery, Lead Design, Drug Repurposing, Deep Learning, Active Data Parsing, Bot Modeling, Biological Interpretation

Services & Products

AI Drug Discovery

Target Identification

Lead Optimization

AI SaaS & API Solutions

Pipeline Development

Target Customers

Pharmaceutical Companies Biotechnology Firms Research Institutions Healthcare Providers Labs looking for AI solutions

Funding Rounds & Investors (8)

View All

Funding Stage	Amount	Investors	Lead Investors	Date
Growth Equity VC	$10.00M	1	Pavilion Capital	01 Jul 2021
Growth Equity VC	$44.50M	11	Atinum Investment, Kakao Ventures +9	01 Mar 2021
Series B	$8.60M	-		01 Nov 2019
Series B	$11.50M	6	Atinum Investment, Kakao Ventures +4	01 Mar 2019
Series A	$3.00M	3	Atinum Investment, Kakao Ventures +1	01 Aug 2016
Seed	$250.00K	1	Kakao Ventures	01 Jan 2016
Seed	$440.00K	1	Korea Tech Incubator Program For Startup	01 Oct 2015
Seed	$280.00K	-		01 May 2015

Standigm Alternatives & Competitors

View All Alternatives

Standigm vs

Variational AI Canada

State-of-the-art generative AI for small molecule drug discovery

Seed

23 employees

AI, Biotechnology

Standigm vs

DeepLife France

AI for digital twin of cells

Series A

29 employees

AI, Biotechnology

Standigm vs

Accutar Biotech United States

Employ AI to Revolutionize Drug Discovery

38 employees

AI, Biopharma

Also compare with:

Deargen

Genesis Molecular AI

Transition Bio, Inc. View all alternatives

FAQ About Standigm

The workflow AI drug discovery company

Standigm was founded in 2015.

Standigm is headquartered in Korea South. As of Nov 2026, it also has offices in ‏Seoul‏، ‏06234‏، ‏KR‏, ‏Seoul‏، ‏06234‏، ‏KR‏, ‏Cambridge‏، ‏England‏ ‏CB1 2JH‏، ‏GB‏, ‏Cambridge‏، ‏England‏ ‏CB1 2JH‏، ‏GB‏ and ‏Cambridge‏، ‏MA‏ ‏02142‏، ‏US‏, ‏Cambridge‏، ‏MA‏ ‏02142‏، ‏US‏.

Standigm operates in AI, Biotechnology, Health Care, Pharmaceutical and Machine Learning. Its work centres on AI-driven Drug Discovery, Workflow Automation, Molecular Design and Novel Target Identification. Its customers include Pharmaceutical Companies, Biotechnology Firms and Research Institutions.

Standigm has a B2B, SaaS and Platform business model. Its revenue comes from Subscription, Licensing and Performance Based.

Standigm has approximately 23 employees.

Standigm has completed 8 funding rounds, raising a total of $78.57M. The latest funding stage is Growth.

Standigm offers: AI Drug Discovery, Target Identification, Lead Optimization, AI SaaS & API Solutions, Pipeline Development.

Top alternatives and competitors to Standigm include Variational AI, DeepLife, Accutar Biotech, Deargen, ONCOCROSS Co., Ltd.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.

Standigm and Variational AI are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Standigm, https://www.bouncewatch.com/company/standigm, updated 21 September 2026. When citing, please name BounceWatch and link this page.